MedPath

Phentolamine

Generic Name
Phentolamine
Brand Names
Oraverse
Drug Type
Small Molecule
Chemical Formula
C17H19N3O
CAS Number
50-60-2
Unique Ingredient Identifier
Z468598HBV
Background

Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine. It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis. Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.

Indication

1.用于预防和治疗嗜铬细胞瘤所致的高血压发作,包括手术切除时出现的阵发性高血压,也可根据血压对本品的反应用于协助诊断嗜铬细胞瘤;

2.治疗左心衰竭;

3.治疗去甲肾上腺素、去氧肾上腺素、间羟胺等静脉给药外溢,用于防止皮肤坏死;

4.临床还用于治疗男性勃起功能障碍(ED)。最新研究表明,本品与罂粟碱、前列地尔三联用药,可降低引起平滑肌收缩的交感神经张力,使阴茎动脉平滑肌松弛,增加阴茎动脉血流,有利勃起。

Associated Conditions
Mydriasis, Necrosis caused by norepinephrine extravasation, Pheochromocytoma, Sloughing Skin, Soft Tissue Anesthesia (Numbness), Hypertensive episodes

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

Phase 4
Completed
Conditions
Anesthesia, Local
Dental Anesthesia
Anesthesia, Reversal
Interventions
Other: Sham injection
First Posted Date
2011-11-18
Last Posted Date
2014-08-29
Lead Sponsor
Novocol Pharmaceutical of Canada, Inc.
Target Recruit Count
150
Registration Number
NCT01474382
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Indiana University School of Dentistry, Indianapolis, Indiana, United States

🇺🇸

University of Pennsylvania School of Dental, Philadelphia, Pennsylvania, United States

and more 4 locations

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures

Phase 3
Completed
Conditions
Anesthesia, Dental
First Posted Date
2006-03-31
Last Posted Date
2006-11-17
Lead Sponsor
Novalar Pharmaceuticals, Inc.
Target Recruit Count
240
Registration Number
NCT00309335
Locations
🇺🇸

Tufts University School of Dental Medicine, Boston, Massachusetts, United States

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

Phase 2
Completed
Conditions
Anesthesia, Dental
First Posted Date
2006-03-31
Last Posted Date
2006-11-17
Lead Sponsor
Novalar Pharmaceuticals, Inc.
Target Recruit Count
150
Registration Number
NCT00309322
Locations
🇺🇸

The Forsyth Institute, Boston, Massachusetts, United States

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures

Phase 3
Completed
Conditions
Anesthesia, Dental
First Posted Date
2006-03-31
Last Posted Date
2006-11-17
Lead Sponsor
Novalar Pharmaceuticals, Inc.
Target Recruit Count
240
Registration Number
NCT00309361
Locations
🇺🇸

Tufts School of Dental Medicine, Boston, Massachusetts, United States

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Not Applicable
Completed
Conditions
CVA (Cerebrovascular Accident)
Cerebral Hemorrhage
Intracranial Hemorrhages
First Posted Date
2005-09-26
Last Posted Date
2008-06-26
Lead Sponsor
The George Institute
Target Recruit Count
404
Registration Number
NCT00226096
Locations
🇦🇺

Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇦🇺

Royal Melbourne Hospital, Melbourne, Victoria, Australia

and more 16 locations

The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

Not Applicable
Conditions
Heart Failure, Congestive
First Posted Date
2005-08-19
Last Posted Date
2007-08-31
Lead Sponsor
Radboud University Medical Center
Registration Number
NCT00132106
Locations
🇳🇱

Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2004-04-08
Last Posted Date
2012-07-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
111
Registration Number
NCT00080808
Locations
🇺🇸

M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath